May 27, 2021

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, vaccines

• A randomized trial of the Pfizer-BioNTech vaccine (BNT162b2) among adolescents ages 12-15 reported vaccine efficacy of 100% (75.3-100%) against COVID-19 for the 2-dose vaccine series. There were 16 cases of COVID-19 among 1,129 placebo recipients and no COVID-19 cases among 1,131 vaccine recipients that occurred 7 or more days after the second dose among participants without evidence of prior SARS-CoV-2 infection. Slightly more BNT162b recipients than placebo recipients (3% vs. 2%) reported related adverse events. There were no vaccine-related serious adverse events.

Frenck et al. (May 27, 2021). Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2107456